The National Cancer Institute (NCI) is offering this grant to facilitate well-planned clinical trials across the cancer prevention and control spectrum. This grant is for the purpose of improving prevention, health behaviors, screening, early detection, healthcare delivery, symptom management, supportive care, and long-term outcomes for cancer survivors. Often, investigators lack critical information regarding study populations, accrual challenges, interventions, or operational risks, leading to costly protocol changes and study delays. Preparatory studies, supported by this grant, will fill these information gaps and test the feasibility of new trial designs. This initiative aims to enhance trial design, improve knowledge of trial feasibility, and ultimately save NCI time and resources by ensuring more efficient and successful clinical trial execution.
Opportunity ID: 356979
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-25-104 |
| Funding Opportunity Title: | Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.399 — Cancer Control |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 05, 2024 |
| Last Updated Date: | Nov 05, 2024 |
| Original Closing Date for Applications: | Oct 25, 2027 |
| Current Closing Date for Applications: | Oct 25, 2027 |
| Archive Date: | Nov 30, 2027 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Public housing authorities/Indian housing authorities Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) For profit organizations other than small businesses City or township governments County governments Independent school districts Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Private institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-25-104.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 356979 Full Announcement-PAR-25-104 -> PAR-25-104-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00288474 | Jan 25, 2025 | Oct 25, 2027 | View |
Package 1
Mandatory forms
356979 RR_SF424_5_0-5.0.pdf
356979 PHS398_CoverPageSupplement_5_0-5.0.pdf
356979 RR_OtherProjectInfo_1_4-1.4.pdf
356979 PerformanceSite_4_0-4.0.pdf
356979 RR_KeyPersonExpanded_4_0-4.0.pdf
356979 PHS398_ResearchPlan_5_0-5.0.pdf
356979 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
356979 RR_Budget_3_0-3.0.pdf
356979 RR_SubawardBudget30_3_0-3.0.pdf
356979 PHS398_ModularBudget_1_2-1.2.pdf
356979 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
